Editas Medicine Inc EDIT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $2.98
- Day Range
- $2.87–3.05
- 52-Week Range
- $1.67–4.53
- Bid/Ask
- $2.90 / $2.91
- Shares Outstanding
- 153.46M
- Market Cap
- $445.04M
- Volume/Avg
- 616,672 / 2M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 7.12
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 87
- Website
- https://www.editasmedicine.com
Valuation
|
Metric
|
EDIT
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 66.19 |
Price/Sales | 7.12 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
EDIT
|
|---|---|
Quick Ratio | 3.17 |
Current Ratio | 3.22 |
Interest Coverage | −22.03 |
Quick Ratio
EDIT
Profitability
|
Metric
|
EDIT
|
|---|---|
Return on Assets (Normalized) | −34.44% |
Return on Equity (Normalized) | −274.95% |
Return on Invested Capital (Normalized) | −152.68% |
Return on Assets
EDIT
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|#&gyz%@ | LOCK|LL<< | $123B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|Nnq!xm& | LOCK|Vz#Jr | $71B | |||
| argenx SE ADR
ARGX
| LOCK|@^&WY^ | LOCK|@!h | $54B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|>TLV!& | LOCK|gy& | $36B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|gS<X<M | LOCK|nZvh | $36B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|>@S!Zl>> | LOCK|ScNb# | $26B | |||
| Moderna Inc
MRNA
| LOCK|@^&q>! | LOCK|>sz | $25B | |||
| Incyte Corp
INCY
| LOCK|dt@%?q? | LOCK|p& | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|#>^fsk< | LOCK|d## | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|&@#NmnD | LOCK|HG | $16B |
United States